北京九强生物技术股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 注：①表中非经营性占用部分，关联方范围依照《创业板上市规则》确定。 ②无控股股东、实际控制人的公司，存在第一大股东或第一大股东关联人非经营性占用资金的，也应填写本表非经营性占用部分。 公司法定代表人：邹左军 主管会计工作的公司负责人: 刘伟 公司会计机构负责人：刘伟 编制单位：北京九强生物技术股份有限公司 单位：万元 | 非经营性资金占用 | | 占用方与上 市公司的关 | 上市公司核算 | 初占用资 | 2025 占用累计发生金 | | 度占用资金的 | 资金占用 | | 年半年度 | | 年半年 | 年半年 | 占用形 | | | 年期 | 2025 年半年 | | | 2025 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 方名称 | | 的会计科目 | | | | ...

证券代码：300406 证券简称：九强生物 公告编号：2025-061 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 第五届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京九强生物技术股份有限公司（以下简称"公司")第五届监事会第 十三次会议（以下简称"本次会议"）通知于 2025 年 8 月 15 日以书面及电 子邮件方式向全体监事发出，与会的各位监事已知悉与所审议事项相关的必 要信息。本次会议于 2025 年 8 月 26 日在公司会议室以现场方式召开。出席 会议的监事应到 3 名，实到监事 3 名，会议由公司监事会主席姜韬先生主持， 张威亚、包楠监事出席了会议。 本次会议的通知、召集、召开和表决符合《中华人民共和国公司法》《公 司章程》及相关法律法规的规定。 二、监事会会议审议情况 与会监事对本次会议需审议的议案进行了充分讨论，审议通过了以下议 案： 本议案在公司2024年年度股东大会决议授权范围内，无需再次提交股东 大会审议。 表决结果：3 票同意，0 票反对，0 票弃 ...

证券代码：300406 证券简称：九强生物 公告编号：2025-060 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 第五届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京九强生物技术股份有限公司(以下简称"公司")第五届董事会第十 七次会议（以下简称"本次会议"）通知于 2025 年 8 月 15 日以电子邮件及 书面方式发出。本次会议于 2025 年 8 月 26 日以现场会议方式在北京市海淀 区花园东路 15 号旷怡大厦 5 层公司会议室召开。由公司董事长邹左军主持， 公司副董事长梁红军，董事刘希、罗爱平、孙小林、王小亚、陈永宏、杨建 平、叶军出席了会议。公司监事及高级管理人员列席了本次会议。 本次会议的通知、召集、召开和表决符合《中华人民共和国公司法》《公 司章程》及相关法律法规的规定。 为进一步提高分红频次，增强投资者回报水平，根据《中华人民共和国 公司法》《公司章程》等相关规定，综合考虑股东利益及公司长远发展需求， 公司2025年中期利润分配方案为：以未来实施利润分 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： （一）分配比例：每 10 股派发现金 3.00 元人民币（含税），2025 年 半年度，不进行资本公积转增股本，不送红股。 证券代码：300406 证券简称：九强生物 公告编号：2025-064 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 关于2025年中期利润分配方案的公告 （二）本次中期利润分配方案，拟以未来实施利润分配方案时股权登 记日的股份总数减去公司回购专用证券账户不参与分配的股份为基数，股 权登记日将在后续发布的权益分派实施公告中具体明确。 因公司发行的可转换公司债券（债券简称：九强转债、债券代码： 123150）目前尚在转股期，在本次利润分配方案公布后至实施前，公司总 股本由于可转债转股等原因发生变化的，公司将以实施利润分配股权登记 日的总股本为基数，按照"分配比例不变"的原则（即向全体股东每 10 股 派发现金红利人民币 3.00 元（含税）,不进行资本公积转增股本，不送红 股），对现金分红总额进行相应调整。 （三）本次中期利润分配方案已经公司第五届董事会 ...

Core Viewpoint - Beijing Jiukang Biotechnology Co., Ltd. has announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 3.00 RMB per 10 shares (including tax) without capital reserve conversion or bonus shares [1][3][4]. Group 1: Profit Distribution Plan - The mid-term profit distribution plan has been approved by the company's board of directors and does not require further approval from the shareholders' meeting [2][3]. - The total number of shares eligible for the cash dividend is calculated as the total shares minus those in the company's repurchase account, resulting in 582,764,544 shares eligible for distribution [3][4]. - The total cash dividend to be distributed amounts to 174,829,363.20 RMB (including tax) based on the eligible shares [4][5]. Group 2: Approval Process - The profit distribution plan was discussed and approved during the annual shareholders' meeting held on April 21, 2025, and subsequently by the board of directors on August 26, 2025 [2][3]. - The supervisory board also reviewed and approved the profit distribution plan, confirming it aligns with the company's operational needs and does not harm the interests of shareholders, especially minority shareholders [2][3]. Group 3: Legal and Compliance - The profit distribution plan complies with relevant laws and regulations, including the Company Law of the People's Republic of China and the company's articles of association [4][5]. - The company will issue further announcements regarding the implementation details, including the record date and ex-dividend date [5].

九强生物公告，2025年上半年营业收入6.68亿元，同比下降18.67%。净利润1.75亿元，同比下降 30.01%。公司拟向全体股东每10股派发现金红利3元（含税）。 ...

Section I Important Notice, Table of Contents and Definitions [Important Notice](index=2&type=section&id=重要提示) The company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, assuming legal responsibility. - The company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, with no false statements, misleading representations, or major omissions, and assume individual and joint legal responsibility[4](index=4&type=chunk) - Company head Zou Zuojun, chief accountant Liu Wei, and head of accounting department Liu Wei declare that the financial report in this semi-annual report is true, accurate, and complete[4](index=4&type=chunk) - Forward-looking statements in this semi-annual report, such as future plans or strategies, do not constitute a substantive commitment by the company to investors, who should maintain sufficient risk awareness regarding them[4](index=4&type=chunk) [Risk Factors](index=2&type=section&id=风险提示) The company faces multiple risks including intensified industry competition, policy changes, new product R&D and registration, and reliance on imported raw materials, addressing these through strategic transformation, R&D investment, policy monitoring, and supply chain optimization. [(I) Risk of Intensified Industry Competition](index=2&type=section&id=(一)%20行业竞争加剧风险) The in-vitro diagnostics (IVD) market faces escalating competition, with foreign brands dominating high-end segments and domestic brands accelerating substitution, leading to product homogenization and price competition. - The in-vitro diagnostics market competition is intensifying, evolving from single-product competition to comprehensive strength competition, including product series and solutions[5](index=5&type=chunk) - The pathology diagnostics sector shows a competitive landscape where foreign capital dominates the high-end market, coexisting with accelerated substitution by domestic brands, and new technology applications intensify market competition[6](index=6&type=chunk) - The company plans to address competition by accelerating strategic transformation, enriching product lines, strengthening sales network construction, enhancing academic marketing, expanding market reach, improving product quality and brand building, and elevating customer service[9](index=9&type=chunk) [(II) Industry Policy Risk](index=5&type=section&id=(二)%20行业政策风险) The medical device industry faces strict national regulation, with policies like centralized procurement and DRG/DIP reducing terminal prices and limiting pricing power, accelerating industry consolidation. - Centralized procurement has gradually covered over 120 types of diagnostic reagents across 8 major categories, including chemiluminescence and molecular diagnostics, leading to lower terminal prices[11](index=11&type=chunk) - Policies such as "Sunshine Procurement," "Centralized Procurement," "DRG/DIP," and national price linkage mechanisms further compress manufacturers' pricing margins[11](index=11&type=chunk) - The company will closely monitor the latest industry policies, promptly formulate countermeasures, flexibly adjust operating strategies, continuously improve its distributor system, and enhance production management levels[11](index=11&type=chunk) [(III) New Product R&D and Registration Risk](index=5&type=section&id=(三)%20新产品研发和注册风险) The technology-intensive in-vitro diagnostics industry faces long R&D cycles, high conversion risks, and stringent, lengthy product registration processes in both domestic and international markets. - R&D outcomes in the in-vitro diagnostics industry typically take one year or more to transform from laboratory technology to products, posing risks of technical deviation or R&D process setbacks leading to failure[12](index=12&type=chunk) - After successful new product R&D, market access requires stages of product standard approval, clinical trials, registration testing, and registration approval, with Chinese approval processes generally taking 1-2 years[13](index=13&type=chunk) - The company will increase R&D investment, strengthen communication with end-users, and stabilize and expand its registration team to improve registration efficiency and shorten time-to-market[13](index=13&type=chunk) [(IV) Risk of Reliance on Imported Upstream Raw Materials](index=6&type=section&id=(四)%20上游原料供应依赖进口的风险) China's biochemical raw material preparation technology is nascent, leading to a high reliance on imported core raw materials for in-vitro diagnostic reagents, posing supply chain risks due to global instability. - Domestic enterprises producing core raw materials for in-vitro diagnostic reagents still primarily rely on imports, posing risks of supply shortages or instability[14](index=14&type=chunk) - The company's countermeasures include maintaining multiple suppliers for the same raw material and increasing R&D investment to achieve domestic substitution[14](index=14&type=chunk) Imported Raw Material Procurement Amount as a Percentage of Total | Year/Period | Percentage | | :---------- | :--- | | 2022 | 16.91% | | 2023 | 17.33% | | 2024 | 14.25% | | H1 2025 | 20.50% | [(V) Management Risk from Business Integration and Scale Expansion](index=7&type=section&id=(五)%20业务整合、规模扩大带来的管理风险) Expanding through M&A and new business areas increases management complexity, posing challenges for business integration and operational efficiency, which could weaken core competitiveness if not adequately addressed. - The company's M&A and new business expansion demand higher management standards, potentially leading to challenges in business integration and improving overall operational efficiency[16](index=16&type=chunk) - The company will continuously conduct operational analysis, promptly optimize its organizational structure and management model, ensuring orderly and efficient operation across all business lines[16](index=16&type=chunk) - The company's profit distribution plan, approved by the Board of Directors, is to distribute a cash dividend of **RMB 3** (tax inclusive) per 10 shares, with no bonus shares or capital increase from capital reserves[16](index=16&type=chunk) [Table of Contents](index=8&type=section&id=目录) This section presents the structured table of contents for the report, including eight main chapters with their starting page numbers and a list of reference documents. - The report's table of contents includes eight main chapters, covering important notices, company profile, management discussion and analysis, corporate governance, significant matters, share changes, bond information, and financial reports[19](index=19&type=chunk) - The list of reference documents includes the original semi-annual report signed by the legal representative, financial statements, and original announcements of all publicly disclosed company documents[21](index=21&type=chunk)[22](index=22&type=chunk)[23](index=23&type=chunk) [Definitions](index=10&type=section&id=释义) This section defines common terms used in the report, including company names, reporting period, stock exchange, industry acronyms like IVD, and certifications such as EU CE and US FDA. - "Strong Biotechnologies" or "the Company" refers to Beijing Strong Biotechnologies, Inc[25](index=25&type=chunk) - "Reporting Period" refers to January 1, 2025, to June 30, 2025[25](index=25&type=chunk) - "IVD" is an abbreviation for In-Vitro Diagnostics[25](index=25&type=chunk) - "CE" is the European Union certification for products, indicating compliance with EU directive safety requirements; "FDA" is the U.S. Food and Drug Administration's evaluation process for product safety and effectiveness for market entry in the United States[25](index=25&type=chunk) Section II Company Profile and Key Financial Indicators [I. Company Profile](index=11&type=section&id=一、公司简介) This section provides basic information about Beijing Strong Biotechnologies, Inc., including its stock ticker, code, listing exchange, Chinese and English names, and legal representative. Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Strong Biotechnologies | | Stock Code | 300406 | | Stock Exchange | Shenzhen Stock Exchange | | Company's Chinese Name | 北京九强生物技术股份有限公司 | | Company's Legal Representative | Zou Zuojun | [II. Contact Person and Information](index=11&type=section&id=二、联系人和联系方式) This section provides contact details for the company's Board Secretary and Securities Affairs Representative, including names, addresses, phone numbers, fax, and email, for investor communication. Contact Person and Information | Position | Board Secretary | Securities Affairs Representative | | :--- | :--- | :--- | | Name | Wang Jianmin | Bao Nan | | Contact Address | 5th Floor, Kuangyi Building, No. 15 Huayuan East Road, Haidian District, Beijing | 5th Floor, Kuangyi Building, No. 15 Huayuan East Road, Haidian District, Beijing | | Phone | 010-82247199 | 010-82247199 | | Email | jiuqiangzhengquan@bsbe.com.cn | jiuqiangzhengquan@bsbe.com.cn | [III. Other Information](index=11&type=section&id=三、其他情况) During the reporting period, there were no changes to the company's registered address, office address, website, email, information disclosure and filing locations, or registration status. - The company's registered address, office address, website, and email remained unchanged during the reporting period, as detailed in the 2024 Annual Report[29](index=29&type=chunk) - Information disclosure and filing locations remained unchanged during the reporting period, as detailed in the 2024 Annual Report[30](index=30&type=chunk) - The company's registration status remained unchanged during the reporting period, as detailed in the 2024 Annual Report[31](index=31&type=chunk) [IV. Key Accounting Data and Financial Indicators](index=12&type=section&id=四、主要会计数据和财务指标) In H1 2025, the company's operating revenue and net profit attributable to shareholders decreased by 18.67% and 30.01% respectively, while net cash flow from operating activities increased by 9.71%. Key Accounting Data and Financial Indicators (Current Reporting Period vs. Same Period Last Year) | Indicator | Current Reporting Period (RMB) | Same Period Last Year (RMB) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 668,335,957.13 | 821,722,324.81 | -18.67% | | Net Profit Attributable to Shareholders of Listed Company | 175,233,795.64 | 250,373,606.97 | -30.01% | | Net Profit Attributable to Shareholders of Listed Company (Excluding Non-Recurring Gains/Losses) | 173,456,836.36 | 248,090,493.65 | -30.08% | | Net Cash Flow from Operating Activities | 244,076,650.72 | 222,466,764.72 | 9.71% | | Basic Earnings Per Share (RMB/share) | 0.30 | 0.43 | -30.23% | | Diluted Earnings Per Share (RMB/share) | 0.30 | 0.43 | -30.23% | | Weighted Average Return on Net Assets | 4.22% | 6.53% | -2.31% | Key Accounting Data and Financial Indicators (End of Current Reporting Period vs. End of Previous Year) | Indicator | End of Current Reporting Period (RMB) | End of Previous Year (RMB) | Change | | :--- | :--- | :--- | :--- | | Total Assets | 5,442,024,152.50 | 5,574,965,162.35 | -2.38% | | Net Assets Attributable to Shareholders of Listed Company | 4,078,022,542.14 | 4,138,374,136.02 | -1.46% | [V. Differences in Accounting Data Under Domestic and International Accounting Standards](index=12&type=section&id=五、境内外会计准则下会计数据差异) During the reporting period, there were no differences in net profit and net assets between financial reports disclosed under international or overseas accounting standards and Chinese accounting standards. - The company's financial reports for the reporting period show no differences in net profit and net assets when disclosed under international accounting standards versus Chinese accounting standards[33](index=33&type=chunk) - The company's financial reports for the reporting period show no differences in net profit and net assets when disclosed under overseas accounting standards versus Chinese accounting standards[34](index=34&type=chunk) [VI. Non-Recurring Gains and Losses Items and Amounts](index=12&type=section&id=六、非经常性损益项目及金额) During the reporting period, the company's total non-recurring gains and losses amounted to RMB 1,776,959.28, primarily from non-current asset disposal, government grants, and other non-operating income/expenses. Non-Recurring Gains and Losses Items and Amounts | Item | Amount (RMB) | | :--- | :--- | | Gains or losses from disposal of non-current assets | -749,603.05 | | Government grants recognized in current profit or loss | 3,286,887.22 | | Other non-operating income and expenses apart from the above | -442,647.85 | | Less: Income tax impact | 314,098.82 | | Impact on minority interests (after tax) | 3,578.22 | | Total | 1,776,959.28 | - The company has no other profit or loss items that meet the definition of non-recurring gains and losses, nor has it classified non-recurring gains and losses as recurring gains and losses[37](index=37&type=chunk) Section III Management Discussion and Analysis [I. Main Business Activities During the Reporting Period](index=14&type=section&id=一、报告期内公司从事的主要业务) The company primarily engages in in-vitro diagnostics (IVD) products and services across pathology, biochemistry, immunology, molecular, and coagulation, expanding its product lines and market reach through R&D and M&A. [(I) Industry Overview](index=14&type=section&id=(一)%20所处行业概况) The company operates in the in-vitro diagnostics (IVD) industry, a critical segment of pharmaceutical manufacturing, characterized by significant market growth potential in China but facing multiple barriers including technology, talent, and market access. [1. Industry Fundamentals](index=14&type=section&id=1、行业基本情况) The in-vitro diagnostics (IVD) industry is a key segment of pharmaceutical manufacturing, encompassing various diagnostic categories like pathology, biochemistry, immunology, and molecular diagnostics, with increasing demand in thrombosis and hemostasis. - Sub-segments of in-vitro diagnostic products include pathology diagnostics, biochemical diagnostics, immunological diagnostics, molecular diagnostics, POCT (Point-of-Care Testing), coagulation diagnostics, and hematology[39](index=39&type=chunk) - Immunodiagnostics is the fastest-growing segment of China's IVD industry from 2020-2025, with chemiluminescence technology gradually replacing traditional methods[41](index=41&type=chunk) - Domestic demand for thrombosis and hemostasis products is continuously increasing, indicating broad future growth potential[41](index=41&type=chunk) [2. Market Landscape](index=14&type=section&id=2、市场格局) The global IVD market is dominated by developed economies and international giants, while China is projected to become the largest consumer by 2030, driven by policy and demographic dividends, with centralized procurement accelerating industry consolidation. - The global IVD market size is projected to grow at a compound annual rate exceeding **5%** from 2020-2027, with developed economies like North America, Europe, and Japan holding major shares[42](index=42&type=chunk)[43](index=43&type=chunk) - China's IVD market size is expected to grow to **RMB 288.15 billion** by 2030, increasing its share in the global market to **33.2%** and becoming the largest consumer of in-vitro diagnostic products[44](index=44&type=chunk) - Centralized procurement has led to reagent price reductions of **50-80%**, which, combined with policies like DRG, accelerates industry consolidation, offering rapid development opportunities for leading enterprises with technological barriers, economies of scale, and innovation capabilities[45](index=45&type=chunk) [3. Industry Barriers](index=15&type=section&id=3、行业壁垒) The in-vitro diagnostics industry faces significant barriers including complex technology, scarcity of interdisciplinary talent, high investment in marketing channels, stringent quality control, and strict market entry regulations. - **Technical barriers**: In-vitro diagnostics is a multidisciplinary field with high technical complexity, requiring continuous R&D investment to maintain competitiveness[46](index=46&type=chunk) - **Talent barriers**: Domestic scarcity of interdisciplinary technical talent makes it difficult for new entrants to quickly build core R&D teams[46](index=46&type=chunk) - **Marketing channel barriers**: Building a professional, extensive marketing network and after-sales service system requires substantial capital investment and time accumulation[47](index=47&type=chunk) - **Market access barriers**: National regulatory authorities implement strict licensing and registration systems for manufacturing and operating enterprises and products, with lengthy approval cycles[47](index=47&type=chunk) [(II) Main Business Introduction](index=15&type=section&id=(二)%20主营业务简介) As a leading in-vitro diagnostics enterprise, the company has developed seven major diagnostic systems over 20 years, leveraging R&D and subsidiary expertise to master core technologies and expand product lines. [1. Overview of Main Business](index=15&type=section&id=1、主要业务概况) With 20 years in in-vitro diagnostics, the company has built seven diverse, high-quality diagnostic systems, including pathology, biochemistry, and coagulation, while its subsidiary Maixin Bio focuses on pathology and AI. - The company, as one of the leading enterprises in China's in-vitro diagnostics industry, has been deeply involved in the field for **20 years**, committed to building a diversified, high-quality in-vitro diagnostic testing platform[49](index=49&type=chunk) - Currently, it possesses seven major diagnostic systems: pathology diagnostic system, biochemical diagnostic system, coagulation diagnostic system, luminescence diagnostic system, blood typing diagnostic system, POCT diagnostic system, and liquid biopsy system[49](index=49&type=chunk) - Wholly-owned subsidiary Maixin Bio focuses on core pathology diagnostic technologies, establishing a four-dimensional integrated approach of "reagent core raw materials + reagent kit development + innovative instruments + diagnostic services," exploring cutting-edge technologies like companion diagnostics and pathology AI[49](index=49&type=chunk) [2. Main Business Model](index=16&type=section&id=2、主要经营模式) The company's business model integrates procurement, production, and marketing, featuring a "production-to-order" approach and a hybrid distribution strategy combining direct sales and dealership networks. [1) Procurement Model](index=16&type=section&id=1）采购模式) The company's procurement model involves four key stages: planning, supplier selection, price negotiation, and quality control, ensuring product quality through departmental collaboration. - Procurement plans are formulated by the Business Department based on inventory, safety stock, delivery times, and prices[51](index=51&type=chunk) - Supplier selection is conducted by the R&D Department for availability screening and technical standard output, with the Business Department handling admission[52](index=52&type=chunk) - Procurement prices are negotiated and determined by the Business Department with suppliers, generally maintained for at least one year to ensure cost stability[53](index=53&type=chunk) - Quality control is performed by the Quality Department, which evaluates and accepts goods based on arrival verification standards to ensure product quality[54](index=54&type=chunk) [2) Production Model](index=16&type=section&id=2）生产模式) The company employs a "production-to-order" model, aligning production plans with market demand and inventory to minimize stock accumulation, reduce costs, and optimize resource utilization. - The company implements a production-to-order model, guided by market demand, combining order contracts and historical sales data with current inventory to formulate various levels of production plans[55](index=55&type=chunk) - The production process includes formulating weekly plans based on average monthly sales, preparation, sub-packaging, packaging, and warehousing[55](index=55&type=chunk) - The on-demand production model avoids inventory backlog and overcapacity, reduces warehousing costs and capital tie-up, and improves resource utilization efficiency[55](index=55&type=chunk) [3) Marketing Model](index=16&type=section&id=3）营销模式) The company utilizes a hybrid marketing model, primarily distribution for Strong Biotechnologies and direct sales for Maixin Bio, with strict dealer management to ensure market coverage and product promotion. - The company adopts a "distribution and direct sales combined" marketing model, with Strong Biotechnologies primarily using distribution and Maixin Bio primarily using direct sales[56](index=56&type=chunk)[59](index=59&type=chunk) - The company imposes requirements on dealer qualifications and sales capabilities, implements a unified pricing policy, and offers discounts based on sales performance[60](index=60&type=chunk)[61](index=61&type=chunk)[62](index=62&type=chunk) - The company provides after-sales service support to dealers, manages accounts receivable, and strictly restricts cross-regional sales by dealers, imposing penalties for violations[63](index=63&type=chunk)[64](index=64&type=chunk) [Medical Device Business Disclosure Requirements](index=17&type=section&id=医疗器械业务披露要求) The company boasts extensive product lines and technology platforms in pathology, biochemistry, coagulation, luminescence, and blood typing diagnostics, with a significant increase in medical device registrations and FDA certifications. - Wholly-owned subsidiary Maixin Bio possesses mature R&D platforms for IHC-related monoclonal antibodies, reagent kit development, and automated instrument development in the field of pathology diagnostics, and is actively developing molecular diagnostics and pathology AI platforms[66](index=66&type=chunk) - The company's biochemical testing covers routine indicators and continuously develops new projects; in coagulation, it has developed fully automatic coagulometers and their配套检测项目; in luminescence, it has launched high, medium, and low-speed instruments and expanded its reagent menu; in blood typing, it continuously introduces new products[66](index=66&type=chunk) [(I) Quantity Statistics](index=18&type=section&id=(一)%20数量统计) At the end of the reporting period, the company saw significant growth in medical device registration certificates, filing certificates, and FDA certifications, with FDA certifications increasing by 180%. Medical Device Certificate Quantity Statistics | Indicator | End of Reporting Period (units) | Same Period Last Year (units) | | :--- | :--- | :--- | | Medical Device Registration Certificates | 395 | 355 | | Medical Device Filing Certificates | 537 | 440 | | CE Certifications | 96 | 96 | | FDA Certifications | 378 | 135 | - At the end of the reporting period, the number of medical device registration certificates increased by **11.27%** year-on-year, filing certificates by **21.00%**, and FDA certifications by **180.00%**[68](index=68&type=chunk) [(II) Medical Devices Under Registration Application During the Reporting Period](index=18&type=section&id=(二)%20报告期内处于注册申请中的医疗器械) During the reporting period, the company had numerous medical devices under registration application, including 53 domestic and 6 CE applications, covering various diagnostic reagents, mostly in technical review or clinical evaluation. - The company has **53** medical device registration certificate/filing certificate applications, primarily for Class II and Class III products, covering various diagnostic reagents such as immunoglobulins, enzymes, mycophenolic acid, gastrin-17, heparin-binding protein, and coagulation factors[69](index=69&type=chunk)[70](index=70&type=chunk)[71](index=71&type=chunk)[72](index=72&type=chunk)[73](index=73&type=chunk)[74](index=74&type=chunk) - Most registration applications are in the technical review, clinical evaluation, or clinical trial stages, all being first-time registration applications and not classified as innovative medical devices[69](index=69&type=chunk)[70](index=70&type=chunk)[71](index=71&type=chunk)[72](index=72&type=chunk)[73](index=73&type=chunk)[74](index=74&type=chunk) - The company has **6** CE registration applications, primarily for Class B and Class C products, including D-dimer, sodium, potassium, total bile acid, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol assay kits, all in the technical review stage[75](index=75&type=chunk) [(III) Newly Registered, Renewed, or Amended Medical Devices During the Reporting Period](index=23&type=section&id=(三)%20报告期内新增注册、延续注册、变更注册的医疗器械) During the reporting period, the company added, renewed, or amended 195 medical device registrations, including 120 domestic certificates and 75 FDA registrations, primarily for biochemical, immunological, and pathology-related reagents. - During the reporting period, the company newly registered, renewed, or amended **120** medical device registration certificates/filing certificates, covering various diagnostic reagents such as carbon dioxide, β2-microglobulin, cholinesterase, creatine kinase, urea, uric acid, pepsinogen, and cardiac troponin I[76](index=76&type=chunk)[77](index=77&type=chunk)[78](index=78&type=chunk)[79](index=79&type=chunk)[80](index=80&type=chunk)[81](index=81&type=chunk)[82](index=82&type=chunk)[83](index=83&type=chunk)[84](index=84&type=chunk)[85](index=85&type=chunk)[86](index=86&type=chunk)[87](index=87&type=chunk)[88](index=88&type=chunk) - Fuzhou Maixin Bio newly registered a large number of Class I Fluorescence In Situ Hybridization (FISH) probe reagents for detecting gene breakage, amplification, or deletion, providing auxiliary diagnostic information for physicians[82](index=82&type=chunk)[83](index=83&type=chunk)[84](index=84&type=chunk)[85](index=85&type=chunk)[86](index=86&type=chunk)[87](index=87&type=chunk)[88](index=88&type=chunk) - During the reporting period, the company newly registered **75** FDA products, primarily including Fuzhou Maixin Bio's Mouse Monoclonal Anti-Human and Rabbit Monoclonal Anti-Human antibody reagent series, as well as various Dual Color Break Apart Probes and Dual Color Dual Fusion probes, used for auxiliary information in tumor diagnosis[89](index=89&type=chunk)[90](index=90&type=chunk)[91](index=91&type=chunk)[92](index=92&type=chunk)[93](index=93&type=chunk)[94](index=94&type=chunk)[95](index=95&type=chunk)[96](index=96&type=chunk)[97](index=97&type=chunk)[98](index=98&type=chunk)[99](index=99&type=chunk)[100](index=100&type=chunk)[101](index=101&type=chunk)[102](index=102&type=chunk)[103](index=103&type=chunk)[104](index=104&type=chunk)[105](index=105&type=chunk)[106](index=106&type=chunk)[107](index=107&type=chunk)[108](index=108&type=chunk)[109](index=109&type=chunk)[110](index=110&type=chunk)[111](index=111&type=chunk)[112](index=112&type=chunk)[113](index=113&type=chunk)[114](index=114&type=chunk)[115](index=115&type=chunk)[116](index=116&type=chunk)[117](index=117&type=chunk)[118](index=118&type=chunk)[119](index=119&type=chunk)[120](index=120&type=chunk)[121](index=121&type=chunk)[122](index=122&type=chunk)[123](index=123&type=chunk)[124](index=124&type=chunk)[125](index=125&type=chunk)[126](index=126&type=chunk) [II. Analysis of Core Competencies](index=73&type=section&id=二、核心竞争力分析) The company's core competencies include continuous R&D, high-quality standards, diversified product lines, strategic partnerships, a robust marketing system, and strong brand building. [(I) Continuous Improvement in R&D Capabilities](index=73&type=section&id=(一)%20研发能力持续提升) In H1 2025, the company achieved significant R&D milestones, increasing its patent portfolio to 234 with 17 new patents covering calibration models, enzyme mutants, and diagnostic reagents. Patent Certificate Quantity | Indicator | Quantity (units) | | :--- | :--- | | Patent certificates at end of reporting period | 234 | | Patent certificates in same period last year | 217 | - During the reporting period, the company obtained **6** patent authorizations, including a calibration model and method for determining analyte concentration, a 6-phosphoglucose dehydrogenase mutant, a detection reagent and preparation method for novel coronavirus antibodies, and a hematoxylin dye solution suitable for automated immunohistochemistry staining instruments[129](index=129&type=chunk) - During the reporting period, the company applied for **11** new patents, including a rivaroxaban content detection kit, a matrix for humanized antibody calibrators, MDC3600/7600 series fully automatic coagulation analyzers, Gi9000 series fully automatic chemiluminescence immunoassay analyzers, and high-pressure immunohistochemistry systems and methods[130](index=130&type=chunk) [(II) Quality and Brand Advantage](index=75&type=section&id=(二)%20质量与品质优势) The company maintains an international-standard production environment and ISO13485 quality management system, with its reference laboratory achieving CNAS accreditation and global traceability status. - The company has established a quality management system in accordance with ISO13485 and national medical device regulations, undergoing **5** external audits in H1 2025, all with satisfactory results[132](index=132&type=chunk) - The company's reference laboratory passed CNAS (ISO17025 and ISO15195) medical reference laboratory accreditation at the end of 2018, with **16** projects currently accredited, and has joined the Joint Committee for Traceability in Laboratory Medicine (JCTLM) as a global traceability service unit[133](index=133&type=chunk) - The reference laboratory collaborates extensively with institutions such as the China National Institute of Metrology and the National Center for Clinical Laboratories of the National Health Commission to promote standardization in the IVD industry[134](index=134&type=chunk) [(III) Product Advantage](index=75&type=section&id=(三)%20产品优势) As a leading biochemical reagent producer, the company leverages seven R&D platforms and M&A to offer a comprehensive product portfolio, including automated chemiluminescence analyzers and advanced pathology solutions. - The company possesses **seven** biochemical technology R&D platforms, mastering core R&D technologies, and has pioneered the launch of multiple innovative products that fill domestic gaps[135](index=135&type=chunk) - The company has officially entered the immunodiagnostics market, successfully launching medium-to-low speed and ultra-high speed fully automatic chemiluminescence analyzers, and continuously enriching its配套试剂, forming synergy with its biochemical and coagulation product lines[135](index=135&type=chunk) - Wholly-owned subsidiary Maixin Bio has over **30 years** of experience in immunohistochemistry, with product performance reaching or exceeding international leading levels, and is developing molecular and pathology AI, committed to building a "precise, standardized, automated, digital, and intelligent" pathology ecosystem[136](index=136&type=chunk) [(IV) Deepening Cooperation for Synergistic Effects](index=75&type=section&id=(四)%20深化合作发挥协同效应) The company actively collaborates with top-tier distributors like Sinopharm Group to expand sales channels and accelerate performance, achieving mutual benefits in supply chain optimization and brand building. - The company actively engages in close cooperation with first-tier distributors, such as various provincial companies of Sinopharm Group, to rapidly expand sales channels and accelerate company performance growth[137](index=137&type=chunk) - The company steadily promotes comprehensive, deep, and lasting cooperation with Sinopharm, from business对接 to operational synergy, fully leveraging both parties' resource advantages to achieve mutual benefit in supply chain optimization and brand co-building[137](index=137&type=chunk) [(V) Advantage of a Comprehensive Marketing System](index=76&type=section&id=(五)%20完善的营销体系优势) The company builds a comprehensive marketing system by seizing industry opportunities, expanding globally, and enhancing after-sales service, fostering instrument-reagent synergy and strategic partnerships with industry leaders. - Subsidiary Maixin Bio accelerates the entry of fully automatic immunohistochemistry staining systems into hospitals by expanding its agent channels, driving sales of immunohistochemistry reagents and FISH reagents, achieving synergistic development of instruments and reagents[138](index=138&type=chunk) - The company adheres to the "walking with giants" strategy, establishing biochemical strategic partnerships with renowned domestic and international enterprises such as Abbott, Roche, Hitachi, and Mindray, with cooperation with Abbott progressing well and technology transfer revenue continuously growing[139](index=139&type=chunk) - In H1 2025, the company actively participated in industry exhibitions in the UAE, visited markets in Turkey and Saudi Arabia, strengthened channel development in South Asia, Southeast Asia, Europe, and South America, and promoted qualification certification for immunohistochemistry reagents and FISH reagents overseas[140](index=140&type=chunk) - The company continuously optimizes its after-sales service system, providing comprehensive professional training and technical support from reagent use to instrument maintenance, and plans to introduce AI technology to build an intelligent service ecosystem[141](index=141&type=chunk) [(VI) Company Brand Building](index=76&type=section&id=(六)%20公司的品牌建设) The company strengthens its brand strategy through "Quality Foundation" emphasizing R&D-driven quality across the product lifecycle, and "Cultural Immersion" to instill brand values internally. - The company deepens its brand strategy through "Quality Foundation," practicing the "quality starts with R&D" philosophy, forming a full lifecycle quality closed loop by integrating customer needs, supplier collaboration, technical support, and quality control resources[142](index=142&type=chunk) - The company deepens its brand strategy through "Cultural Immersion," adhering to the principle that "a brand should first be established in the minds of internal personnel," building a multi-dimensional brand recognition system to ensure effective penetration of the brand strategy across all organizational levels[143](index=143&type=chunk) [(VII) Building an Academically-Led Industry-University-Research Cooperation Model](index=77&type=section&id=(七)%20打造学术引领的产学研合作模式) The company maintains an academic marketing strategy, participating in national health research projects and successfully completing R&D projects, while fostering collaborative education initiatives. - The company adheres to an academic marketing strategy, utilizing academic conferences, exhibitions, and forums to deepen strategic cooperation with numerous domestic clinical laboratories[144](index=144&type=chunk) - In January 2025, the company's project "Establishment of a Clinical Laboratory Reference System for Cardiovascular and Cerebrovascular Diseases and Research on HCY Reference Intervals in the Elderly Population," participated in by the National Health Commission Hospital Management Institute, was successfully approved[144](index=144&type=chunk) - In February 2025, the company's project "Establishment and Promotion of a Clinical Testing System for Major Chronic Disease Inflammatory Markers," part of the 2024 National Major Science and Technology Project for Cancer, Cardiovascular, Respiratory, and Metabolic Disease Prevention and Control Research, was successfully approved[144](index=144&type=chunk) - In April 2025, the "Development and Industrialization of Fully Automatic Pathology Tissue Staining System" project, submitted by wholly-owned subsidiary Maixin Bio, successfully passed final acceptance[144](index=144&type=chunk) - In H1 2025, the company initiated collaborative education projects, with **3** units applying for and completing project approval, involving research on autoimmune liver disease, Brucella infection, and monitoring of thrombotic indicators in colorectal patients[145](index=145&type=chunk) [(VIII) Awards Received](index=77&type=section&id=(八)%20获奖情况) On January 14, 2025, the company received the "First Prize for Military Science and Technology Progress," recognizing its outstanding contributions to technological innovation. - On January 14, 2025, the company was awarded the "First Prize for Military Science and Technology Progress," a high recognition for its outstanding contributions to technological innovation[146](index=146&type=chunk) [III. Analysis of Main Business](index=77&type=section&id=三、主营业务分析) The company's core business in biochemical and pathology diagnostics saw H1 2025 operating revenue decrease by 18.67% to RMB 668.34 million, primarily due to centralized procurement and VAT rate changes. - The company's core business is biochemical and pathology diagnostics, gradually expanding into coagulation, luminescence, blood typing, and other fields[147](index=147&type=chunk) Operating Revenue and Year-on-Year Change | Indicator | H1 2025 (RMB 10,000) | H1 2024 (RMB 10,000) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 66,833.60 | 82,172.23 | -18.67% | - The decrease in operating revenue is primarily due to the continuous advancement of centralized procurement policies, rapid implementation of DRG, and policies such as mutual recognition of test results; additionally, subsidiary Maixin Bio's VAT rate changed from **3%** to **13%** starting from 2025[147](index=147&type=chunk) - Diagnostic reagent business remains the primary source of operating revenue, accounting for **95.09%** of total operating revenue[147](index=147&type=chunk) Sales Model Revenue and Gross Margin (H1 2025 vs. H1 2024) | Sales Model | H1 2025 Operating Revenue (RMB 10,000) | H1 2025 Gross Margin | H1 2024 Operating Revenue (RMB 10,000) | H1 2024 Gross Margin | | :--- | :--- | :--- | :--- | :--- | | Direct Sales | 32,873.19 | 90.89% | 35,424.05 | 89.86% | | Distribution | 33,960.41 | 68.65% | 46,748.18 | 67.83% | | Subtotal | 66,833.60 | 79.59% | 82,172.23 | 77.33% | - Distribution model revenue accounted for **50.81%** of operating revenue, with sales decreasing by **27.35%** year-on-year; direct sales revenue accounted for **49.19%**, with sales decreasing by **7.20%** year-on-year; the average gross margin increased by **2.26%**, mainly due to the increased proportion of subsidiary Maixin Bio's pathology business[148](index=148&type=chunk) Procurement Amount (H1 2025 vs. H1 2024) | Item | H1 2025 Procurement Amount (RMB 10,000) | H1 2024 Procurement Amount (RMB 10,000) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Raw Materials | 7,599.84 | 8,146.76 | -6.71% | | Agency Reagents | 4,159.97 | 7,547.32 | -44.88% | | Instruments | 1,069.28 | 1,570.18 | -31.90% | | Total | 12,829.10 | 17,264.26 | -25.69% | Major Financial Data Year-on-Year Change | Indicator | Current Reporting Period (RMB) | Same Period Last Year (RMB) | Year-on-Year Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 668,335,957.13 | 821,722,324.81 | -18.67% | | | Operating Cost | 136,402,199.32 | 186,299,645.98 | -26.78% | | | Selling Expenses | 148,144,549.11 | 147,674,341.51 | 0.32% | | | Administrative Expenses | 63,385,975.74 | 69,914,142.33 | -9.34% | | | Financial Expenses | 20,002,948.12 | 20,343,818.12 | -1.68% | | | Income Tax Expense | 20,670,296.99 | 50,987,663.65 | -59.46% | Primarily due to decreased profit | | R&D Investment | 84,329,001.80 | 86,944,037.45 | -3.01% | | | Net Cash Flow from Operating Activities | 244,076,650.72 | 222,466,764.72 | 9.71% | | | Net Cash Flow from Investing Activities | -192,930,709.10 | 241,751,436.42 | -179.81% | Primarily due to purchase of large-denomination certificates of deposit in current period | | Net Cash Flow from Financing Activities | -280,795,092.13 | -134,718,051.26 | -108.43% | Primarily due to higher dividend distribution in current period than same period last year | | Net Increase in Cash and Cash Equivalents | -229,722,012.37 | 329,528,728.93 | -169.71% | Primarily due to purchase of large-denomination certificates of deposit and dividend distribution in current period | Product or Service Accounting for Over 10% of Revenue | Product or Service | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Margin | Year-on-Year Change in Operating Revenue | Year-on-Year Change in Operating Cost | Year-on-Year Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | In-vitro Diagnostic Reagents | 635,512,793.08 | 111,606,465.71 | 82.44% | -19.29% | -30.38% | 2.80% | [IV. Analysis of Non-Core Business](index=79&type=section&id=四、非主营业务分析) During the reporting period, non-core business activities included negative investment income from equity-accounted long-term equity investments, and non-operating income/expenses from non-recurring items. Non-Core Business Analysis | Item | Amount (RMB) | Percentage of Total Profit | Explanation of Cause | Sustainability | | :--- | :--- | :--- | :--- | :--- | | Investment Income | -742,471.47 | -0.38% | Primarily from long-term equity investment income accounted for using the equity method | Yes | | Non-Operating Income | 209,790.57 | 0.11% | Income from liquidated damages and amounts not required to be paid | No | | Non-Operating Expenses | 652,438.42 | 0.33% | Loss from disposal of non-current assets | No | [V. Analysis of Assets and Liabilities](index=79&type=section&id=五、资产及负债状况分析) At the end of the reporting period, total assets and net assets attributable to shareholders slightly decreased, with cash and cash equivalents reduced by dividends and large-denomination deposits, while certain assets were restricted. Significant Changes in Asset Composition | Item | Amount at End of Current Reporting Period (RMB) | Percentage of Total Assets | Amount at End of Previous Year (RMB) | Percentage of Total Assets | Change in Proportion | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | 878,336,389.47 | 16.14% | 1,042,657,721.31 | 18.70% | -2.56% | Dividends and purchase of large-denomination certificates of deposit, etc. | | Accounts Receivable | 1,054,265,742.56 | 19.37% | 1,077,474,440.62 | 19.33% | 0.04% | | | Inventories | 223,491,471.20 | 4.11% | 220,680,889.10 | 3.96% | 0.15% | | | Total Assets | 5,442,024,152.50 | | 5,574,965,162.35 | | -2.38% | | | Net Assets Attributable to Shareholders of Listed Company | 4,078,022,542.14 | | 4,138,374,136.02 | | -1.46% | | Significant Changes in Liability Composition | Item | Amount at End of Current Reporting Period (RMB) | Percentage of Total Assets | Amount at End of Previous Year (RMB) | Percentage of Total Assets | Change in Proportion | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Short-term Borrowings | 131,798.56 | 0.00% | 105,861.99 | 0.00% | 0.00% | | | Notes Payable | 6,071,759.85 | 0.11% | 1,185,923.33 | 0.02% | 0.09% | | | Employee Benefits Payable | 27,499,598.00 | 0.51% | 64,953,052.45 | 1.16% | -0.65% | | | Taxes Payable | 30,768,275.50 | 0.57% | 45,309,825.56 | 0.81% | -0.24% | | - Fuzhou Maixin Biotechnology Development Co., Ltd. mortgaged its land use rights and construction in progress, valued at **RMB 101.09 million**, to secure project loans[161](index=161&type=chunk) - The company signed a domestic factoring agreement with China Merchants Bank Liaocheng Branch to apply for financing using accounts receivable; as of the end of the reporting period, the related accounts receivable were not derecognized, and "other current liabilities" were recognized[162](index=162&type=chunk) [VI. Analysis of Investment Status](index=80&type=section&id=六、投资状况分析) During the reporting period, the company's investment amounted to RMB 236.08 million, a 184.00% increase year-on-year, with no significant equity or non-equity investments, wealth management, or derivatives. Investment Amount During the Reporting Period | Indicator | Amount (RMB) | | :--- | :--- | | Investment amount in current reporting period | 236,083,794.81 | | Investment amount in same period last year | 83,127,236.47 | | Change percentage | 184.00% | - The company had no significant equity investments, non-equity investments, entrusted wealth management, derivative investments, or entrusted loans during the reporting period[164](index=164&type=chunk)[165](index=165&type=chunk)[167](index=167&type=chunk)[168](index=168&type=chunk)[169](index=169&type=chunk)[170](index=170&type=chunk) Financial Assets Measured at Fair Value | Asset Category | Initial Investment Cost (RMB) | Amount at End of Period (RMB) | Source of Funds | | :--- | :--- | :--- | :--- | | Other | 30,000,000.00 | 30,000,000.00 | Own funds | [VII. Significant Asset and Equity Disposals](index=81&type=section&id=七、重大资产和股权出售) During the reporting period, the company did not undertake any significant asset or equity disposals. - The company did not sell significant assets during the reporting period[171](index=171&type=chunk) - The company did not sell significant equity during the reporting period[172](index=172&type=chunk) [VIII. Analysis of Major Holding and Participating Companies](index=82&type=section&id=八、主要控股参股公司分析) Fuzhou Maixin Biotechnology Development Co., Ltd. is a key wholly-owned subsidiary, generating RMB 380 million in operating revenue and RMB 167 million in net profit from medical reagent and device sales. Major Subsidiary Financial Data | Company Name | Company Type | Main Business | Registered Capital (RMB) | Total Assets (RMB) | Net Assets (RMB) | Operating Revenue (RMB) | Operating Profit (RMB) | Net Profit (RMB) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Fuzhou Maixin Biotechnology Development Co., Ltd. | Subsidiary | Sales of medical reagents and medical devices | 50,000,000.00 | 1,884,014,304.58 | 1,652,415,083.63 | 380,354,381.27 | 194,214,777.58 | 166,597,334.93 | - The company did not acquire or dispose of any subsidiaries during the reporting period[174](index=174&type=chunk) [IX. Structured Entities Controlled by the Company](index=82&type=section&id=九、公司控制的结构化主体情况) During the reporting period, the company did not control any structured entities. - The company did not control any structured entities during the reporting period[174](index=174&type=chunk) [X. Risks Faced by the Company and Countermeasures](index=82&type=section&id=十、公司面临的风险和应对措施) The company advises investors to thoroughly review the full semi-annual report, paying particular attention to the detailed risk factors outlined in "Section I Important Notice, Table of Contents and Definitions." - The company requests investors to carefully read the full semi-annual report and pay special attention to the risk factors faced by the company, detailed in "Section I Important Notice, Table of Contents and Definitions" of this report[174](index=174&type=chunk) [XI. Registration Form for Research, Communication, and Interview Activities During the Reporting Period](index=82&type=section&id=十一、报告期内接待调研、沟通、采访等活动登记表) On April 16, 2025, the company held its 2024 annual performance online briefing via the Panorama Network investor relations platform, engaging with various investors on its annual operations. Registration Form for Research, Communication, and Interview Activities During the Reporting Period | Reception Time | Reception Location | Reception Method | Type of Reception Object | Main Content Discussed and Materials Provided | | :--- | :--- | :--- | :--- | :--- | | April 16, 2025 | Company held performance briefing via Panorama Network "Investor Relations Interactive Platform" | Online platform communication | Individuals, institutions, others | Annual operations and other related matters | [XII. Formulation and Implementation of Market Value Management System and Valuation Enhancement Plan](index=82&type=section&id=十二、市值管理制度和估值提升计划的制定落实情况) The company adopted a "Market Value Management System" on March 28, 2025, approved by the Board, to enhance corporate governance, but has not disclosed a valuation enhancement plan. - The company has formulated a market value management system, which was reviewed and approved at the fourteenth meeting of the fifth Board of Directors on March 28, 2025, through the "Proposal on Formulating the Market Value Management System"[177](index=177&type=chunk) - The company has not disclosed a valuation enhancement plan[176](index=176&type=chunk) [XIII. Implementation of the 'Dual Enhancement of Quality and Returns' Action Plan](index=83&type=section&id=十三、“质量回报双提升”行动方案贯彻落实情况) The company has not disclosed an announcement regarding its "Dual Enhancement of Quality and Returns" action plan. - The company has not disclosed an announcement regarding the "Dual Enhancement of Quality and Returns" action plan[178](index=178&type=chunk) Section IV Corporate Governance, Environment, and Society [I. Changes in Directors, Supervisors, and Senior Management](index=84&type=section&id=一、公司董事、监事、高级管理人员变动情况) During the reporting period, there were no changes in the company's directors, supervisors, or senior management. - There were no changes in the company's directors, supervisors, and senior management during the reporting period, as detailed in the 2024 Annual Report[180](index=180&type=chunk) [II. Profit Distribution and Capital Reserve Conversion to Share Capital During the Reporting Period](index=84&type=section&id=二、本报告期利润分配及资本公积金转增股本情况) The H1 2025 profit distribution plan proposes a cash dividend of RMB 3.00 (tax inclusive) per 10 shares, totaling RMB 174.83 million, representing 10.34% of distributable profits. H1 2025 Profit Distribution Plan | Indicator | Amount/Quantity | | :--- | :--- | | Number of bonus shares per 10 shares (shares) | 0 | | Dividend per 10 shares (RMB) (tax inclusive) | 3 | | Share capital base for distribution plan (shares) | 582,764,544 | | Cash dividend amount (RMB) (tax inclusive) | 174,829,363.20 | | Total cash dividend (including other forms) as a percentage of total profit distribution | 10.34% | | Distributable profit (RMB) | 1,691,510,224.05 | - The company proposes to distribute a cash dividend of **RMB 3.00** (tax inclusive) per 10 shares to all shareholders, based on the total number of shares on the equity registration date when the profit distribution plan is implemented, minus the 3,544,084 shares in the company's repurchased special securities account that do not participate in the distribution[181](index=181&type=chunk) - If the company's total share capital changes due to convertible bond conversion or other reasons, the total cash dividend will be adjusted accordingly based on the total share capital on the equity registration date for profit distribution, adhering to the "unchanged distribution ratio" principle[181](index=181&type=chunk) [III. Implementation of Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=84&type=section&id=三、公司股权激励计划、员工持股计划或其他员工激励措施的实施情况) In H1 2025, the company approved and completed the repurchase and cancellation of 2,017,966 restricted shares from its fifth equity incentive plan, totaling RMB 18.79 million, due to employee departures and unmet performance targets. - On March 28, 2025, the company's Board of Directors and Supervisory Board reviewed and approved the "Proposal on Repurchasing and Cancelling Part of the Restricted Shares under the Fifth Restricted Stock Incentive Plan"[182](index=182&type=chunk) - A total of **2,017,966** restricted shares were repurchased and cancelled due to the departure of incentive recipients and failure to meet company-level performance targets, with a repurchase price of **RMB 18,787,263.80**[182](index=182&type=chunk) - The repurchase and cancellation of these shares were completed on July 22, 2025[182](index=182&type=chunk) - The company had no employee stock ownership plans or other employee incentive measures during the reporting period[183](index=183&type=chunk) [IV. Environmental Information Disclosure](index=85&type=section&id=四、环境信息披露情况) The company and its major subsidiaries are not included in the list of enterprises required to disclose environmental information by law. - The listed company and its major subsidiaries are not included in the list of enterprises required to disclose environmental information by law[183](index=183&type=chunk) [V. Social Responsibility](index=85&type=section&id=五、社会责任情况) The company upholds social responsibility by safeguarding stakeholder interests, ensuring employee welfare, delivering high-quality products, promoting environmental sustainability, and contributing to public health initiatives. - The company effectively safeguards the interests of the company and its small and medium shareholders by improving corporate governance, strictly disclosing information, actively implementing profit distribution policies, and valuing investor relations management[183](index=183&type=chunk) - The company strictly adheres to labor laws and regulations, pays five social insurances and one housing fund plus supplementary commercial insurance for employees, and prioritizes talent development, employee safety, labor protection, and physical and mental health[185](index=185&type=chunk) - The company adheres to the "quality first" principle, providing high-quality clinical testing items and diversified diagnostic solutions, along with nationwide technical service support[187](index=187&type=chunk) - The company advocates for low-carbon and environmentally friendly green office practices, emphasizes environmental protection, actively promotes energy conservation and emission reduction, achieving coordinated and sustainable development with society and nature[188](index=188&type=chunk) - The company is a co-developer and producer of the CysC national standard, undertakes national high-tech R&D programs, and co-founded the CSTH Coagulation Cloud Classroom with the Chinese Research Hospital Association's Thrombosis and Hemostasis Professional Committee to promote standardization of coagulation testing in grassroots laboratories[189](index=189&type=chunk) Section V Significant Matters [I. Commitments Fulfilled and Overdue Unfulfilled by Controlling Shareholder, Shareholders, Related Parties, Acquirers, and the Company During and as of the End of the Reporting Period](index=87&type=section&id=一、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内履行完毕及截至报告期末超期未履行完毕的承诺事项) During the reporting period, there were no fulfilled or overdue unfulfilled commitments by the company's controlling shareholder, shareholders, related parties, acquirers, or the company itself. - During the reporting period, there were no commitments by the company's actual controller, shareholders, related parties, acquirers, or the company itself that were fulfilled or overdue and unfulfilled as of the end of the reporting period[191](index=191&type=chunk) [II. Non-Operating Fund Occupation by Controlling Shareholder and Other Related Parties](index=87&type=section&id=二、控股股东及其他关联方对上市公司的非经营性占用资金情况) During the reporting period, there was no non-operating occupation of listed company funds by the controlling shareholder or other related parties. - During the reporting period, there was no non-operating occupation of listed company funds by the controlling shareholder or other related parties[192](index=192&type=chunk) [III. Irregular External Guarantees](index=87&type=section&id=三、违规对外担保情况) During the reporting period, the company had no irregular external guarantees. - The company had no irregular external guarantees during the reporting period[193](index=193&type=chunk) [IV. Appointment and Dismissal of Accounting Firms](index=87&type=section&id=四、聘任、解聘会计师事务所情况) The company's semi-annual financial report was not audited. - The company's semi-annual report was not audited[194](index=194&type=chunk) [V. Explanations by the Board of Directors, Supervisory Board, and Audit Committee on the Accounting Firm's 'Non-Standard Audit Report' for the Current Period](index=87&type=section&id=五、董事会、监事会、审计委员会对会计师事务所本报告期“非标准审计报告”的说明) During the reporting period, there were no explanations from the Board, Supervisory Board, or Audit Committee regarding a "non-standard audit report" from the accounting firm. - During the reporting period, there were no explanations from the Board of Directors, Supervisory Board, or Audit Committee regarding the accounting firm's "non-standard audit report" for the current period[195](index=195&type=chunk) [VI. Explanations by the Board of Directors on the 'Non-Standard Audit Report' for the Previous Year](index=87&type=section&id=六、董事会对上年度“非标准审计报告”相关情况的说明) During the reporting period, there were no explanations from the Board of Directors regarding the "non-standard audit report" for the previous year. - During the reporting period, there were no explanations from the Board of Directors regarding the "non-standard audit report" for the previous year[195](index=195&type=chunk) [VII. Matters Related to Bankruptcy Reorganization](index=87&type=section&id=七、破产重整相关事项) During the reporting period, the company had no matters related to bankruptcy reorganization. - The company had no matters related to bankruptcy reorganization during the reporting period[195](index=195&type=chunk) [VIII. Litigation Matters](index=87&type=section&id=八、诉讼事项) During the reporting period, the company had no significant litigation, arbitration, or other legal matters. - The company had no significant litigation or arbitration matters during this reporting period[196](index=196&type=chunk) - The company had no other litigation matters during the reporting period[196](index=196&type=chunk) [IX. Penalties and Rectification](index=88&type=section&id=九、处罚及整改情况) During the reporting period, the company had no penalties or rectification situations. - The company had no penalties or rectification situations during the reporting period[197](index=197&type=chunk) [X. Integrity Status of the Company, its Controlling Shareholder, and Actual Controller](index=88&type=section&id=十、公司及其控股股东、实际控制人的诚信状况) During the reporting period, there were no integrity issues concerning the company, its controlling shareholder, or actual controller. - During the reporting period, there were no integrity issues concerning the company, its controlling shareholder, or actual controller[198](index=198&type=chunk) [XI. Significant Related Party Transactions](index=88&type=section&id=十一、重大关联交易) During the reporting period, the company engaged in routine related party transactions with Sinopharm Holdings and its subsidiaries, including procurement, services, and sales, all within approved limits, and financial dealings with Sinopharm Finance Co., Ltd. Related Party Transactions for Purchase and Sale of Goods, Provision and Acceptance of Services | Related Party | Related Transaction Content | Amount in Current Period (RMB) | Approved Transaction Limit (RMB 10,000) | Exceeded Transaction Limit | Amount in Prior Period (RMB) | | :--- | :--- | :--- | :--- | :--- | :--- | | Sinopharm Holdings Co., Ltd. and its subsidiaries | Purchase of goods | 1,074,611.34 | 1,500 | No | 3,098,194.17 | | Sinopharm Holdings Co., Ltd. and its subsidiaries | Acceptance of services | 508,831.13 | 500 | No | 235,783.25 | | Sinopharm Holdings Co., Ltd. and its subsidiaries | Sale of goods | 27,519,061.38 | 9,000 | No | 35,519,065.11 | - The company signed a "Financial Services Agreement" with Sinopharm Group Finance Co., Ltd., where the daily balance of deposits absorbed by Sinopharm Group Finance Co., Ltd. from the company does not exceed **RMB 200 million**, and a comprehensive credit line of up to **RMB 500 million** is provided[832](index=832&type=chunk) - As of June 30, 2025, the company's deposit balance with Sinopharm Group Finance Co., Ltd. was **RMB 11,642.86**, and the amount of acceptance bills issued by Sinopharm Group Finance Co., Ltd. in the current reporting period was **RMB 11,283,566.68**[833](index=833&type=chunk)[834](index=834&type=chunk) - During the reporting period, the company did not engage in related party transactions involving asset or equity acquisition/disposal, joint external investments, or non-operating related party receivables and payables[203](index=203&type=chunk)[204](index=204&type=chunk)[205](index=205&type=chunk) [XII. Significant Contracts and Their Performance](index=93&type=section&id=十二、重大合同及其履行情况) During the reporting period, the company had no significant entrustment, contracting, guarantees, or other major contracts, but engaged in various leasing activities for warehouses, offices, and equipment, none of which significantly impacted profit. - The company had no entrustment, contracting, significant guarantees, or other significant contracts during the reporting period[211](index=211&type=chunk)[212](index=212&type=chunk)[219](index=219&type=chunk)[222](index=222&type=chunk) - The company leases warehouse space located in Yanqi Economic Development Zone, Huairou District, Beijing, with some lease contracts renewed in December 2023, and rent adjusted upwards by **5%** every three years[214](index=214&type=chunk)[216](index=216&type=chunk) - The company leases office space located at No. 108, Yi, Beiyuan Road, Chaoyang District, Beijing, with a new contract signed on April 1, 2024, for a lease term until September 30, 2027, at a rent of **RMB 4/square meter**[215](index=215&type=chunk) - Subsidiary Fuzhou Maixin leases land located in Hengkeng Village, Baizhang Town, Minqing County, Fuzhou City, with a lease term from May 15, 2015, to May 14, 2040[217](index=217&type=chunk) - Subsidiary Hunan Jiuqiang leases premises located at No. 229 Guyuan Road, Yuelu District, Changsha City, for a lease period from September 20, 2024, to September 19, 2026[218](index=218&type=chunk) - The company had no leasing projects that resulted in profit or loss exceeding **10%** of the company's total profit during the reporting period[218](index=218&type=chunk) [XIII. Explanation of Other Significant Matters](index=95&type=section&id=十三、其他重大事项的说明) During the reporting period, there were no other significant matters requiring explanation by the company. - The company had no other significant matters requiring explanation during the reporting period[223](index=223&type=chunk) [XIV. Significant Matters of Company Subsidiaries](index=95&type=section&id=十四、公司子公司重大事项) During the reporting period, no significant matters occurred within the company's subsidiaries. - The company had no sig

8月21日，北京九强生物（300406）技术股份有限公司（以下简称"九强生物"）官微消息，近日，北京 市科学技术委员会、中关村科技园区管理委员会正式发布《北京市新技术新产品新服务（总第二十批） 公示名单》，九强生物抗Xa测定试剂盒成功入选该名单。 北京市新技术新产品新服务认定，是由北京市科学技术委员会、中关村科技园区管理委员会等多部门联 合开展的重要评选活动，有着严苛的评选标准，旨在筛选出技术水平高、创新性强、具有良好市场前景 和经济效益的产品与服务。入选的产品和服务需经过层层审核，不仅要在核心技术上拥有自主知识产 权，达到国内乃至国际先进水平，还要在改善民生等方面具有突出贡献，同时，对于推动相关产业升 级、促进经济高质量发展也有着积极的引领作用。 九强抗Xa测定试剂盒（发色底物法）线性宽，抗干扰能力强，精密度高，与市场主流厂家试剂相关性 良好，R2>0.95，可满足临床检测需求。 本次九强生物能够入选该名单，是对公司技术创新能力和产品竞争力的高度肯定。未来，九强生物将继 续深耕体外诊断领域，以创新为驱动，为临床提供更多优质、高效的诊断产品与服务，助力医疗行业蓬 勃发展。 ...

Group 1 - Gujia Home achieved a net profit of 1.02 billion yuan in the first half of 2025, a year-on-year increase of 13.89% [1] - Gujia Home's revenue for the first half of 2025 was 9.80 billion yuan, up 10.02% year-on-year [1] - Phoenix Holdings reported a net profit of 11.04 million yuan, successfully turning a profit [1] - Phoenix Holdings' revenue increased by 200.78% year-on-year to 291 million yuan [1] - Zheshang Securities recorded a net profit of 1.15 billion yuan, a year-on-year growth of 46.49% [1] - Zheshang Securities' revenue decreased by 23.66% to 6.11 billion yuan [1] Group 2 - Tianjin Port's net profit was 503 million yuan, a year-on-year decrease of 18.33% [3] - Tianjin Port's revenue for the first half of 2025 was 6.18 billion yuan, an increase of 4.33% year-on-year [3] - Xuantai Pharmaceutical reported a net profit of 45.59 million yuan, down 15.82% year-on-year [5] - Xuantai Pharmaceutical's revenue was 220 million yuan, a slight increase of 0.74% year-on-year [5] Group 3 - Yilida achieved a net profit of 40.03 million yuan, a year-on-year increase of 18.32% [7] - Yilida's revenue for the first half of 2025 was 758 million yuan, up 12.56% year-on-year [7] - Zhongji United reported a net profit of 262 million yuan, a significant year-on-year increase of 86.61% [9] - Zhongji United's revenue was 818 million yuan, a year-on-year growth of 43.52% [9] Group 4 - China Shipbuilding Special Gas reported a net profit of 178 million yuan, a slight decrease of 0.55% year-on-year [10] - China Shipbuilding Special Gas' revenue was 1.04 billion yuan, an increase of 12.60% year-on-year [10] - Xinyuan Intelligent Manufacturing achieved a net profit of 9.79 million yuan, a year-on-year increase of 284.45% [11] - Xinyuan Intelligent Manufacturing's revenue was 329 million yuan, up 388.33% year-on-year [11] Group 5 - Jiudian Pharmaceutical reported a net profit of 291 million yuan, a year-on-year increase of 2.57% [13] - Jiudian Pharmaceutical's revenue was 1.51 billion yuan, a year-on-year growth of 10.67% [13] - Boya Biological reported a net profit of 225 million yuan, down 28.68% year-on-year [15] - Boya Biological's revenue was 1.01 billion yuan, an increase of 12.51% year-on-year [15] Group 6 - True Love Home achieved a net profit of 197 million yuan, a year-on-year increase of 484.48% [17] - True Love Home's revenue was 390 million yuan, up 21.82% year-on-year [17] - Dongfang Electronics reported a net profit of 302 million yuan, a year-on-year increase of 19.65% [19] - Dongfang Electronics' revenue was 3.16 billion yuan, a year-on-year growth of 12.18% [19] Group 7 - Watte Holdings achieved a net profit of 18.41 million yuan, a year-on-year increase of 23.94% [21] - Watte Holdings' revenue was 906 million yuan, up 12.29% year-on-year [21] - Tianqin Equipment reported a net profit of 16.36 million yuan, a year-on-year increase of 2.78% [22] - Tianqin Equipment's revenue was 111 million yuan, a year-on-year growth of 18.42% [22] Group 8 - Yingfeng Environment achieved a net profit of 382 million yuan, a year-on-year increase of 0.43% [24] - Yingfeng Environment's revenue was 6.46 billion yuan, up 3.69% year-on-year [24] - Kexin Machinery reported a net profit of 52.20 million yuan, a year-on-year decrease of 46.18% [26] - Kexin Machinery's revenue was 592 million yuan, down 17.26% year-on-year [26] Group 9 - Tengda Construction reported a net profit of 108 million yuan, a year-on-year decrease of 0.69% [27] - Tengda Construction's revenue was 1.61 billion yuan, down 5.20% year-on-year [27] - Canaan Technology achieved a net profit of 7.35 million yuan, a year-on-year decrease of 38.46% [29] - Canaan Technology's revenue was 560 million yuan, up 1.29% year-on-year [29] Group 10 - Metro Design reported a net profit of 221 million yuan, a year-on-year increase of 6.58% [30] - Metro Design's revenue was 1.32 billion yuan, up 5.31% year-on-year [30] - China Shipbuilding Special Gas plans to use up to 2.9 billion yuan of idle funds for cash management [31] - The company intends to invest in safe, liquid, principal-protected products [31] Group 11 - Jiuchuang Biotechnology received a medical device registration certificate for its lupus anticoagulant detection kit [32] - The product is intended for in vitro qualitative detection of lupus anticoagulant in human plasma [32] - Xinowei's subsidiary received approval for clinical trials of its innovative drug [33] - The drug is a humanized monoclonal antibody intended for treating multiple cancers [33] Group 12 - Dongcheng Pharmaceutical's subsidiary received FDA approval for clinical trials of its targeted radiopharmaceutical [34] - The drug is intended for treating advanced prostate cancer [34] - Shandong Road and Bridge received approval to issue bonds up to 4 billion yuan [35] - The company specializes in road and bridge engineering construction [35] Group 13 - Diou Home plans to invest 500 million yuan to establish a subsidiary focused on generative AI [36] - The investment aims to transform the company into a full-stack industrial intelligent service provider [36] - Dayilong achieved a net profit of 90.87 million yuan, a year-on-year increase of 217.89% [37] - Dayilong's revenue was 957 million yuan, up 57.35% year-on-year [37] Group 14 - Chaohongji reported a net profit of 331 million yuan, a year-on-year increase of 44.34% [38] - Chaohongji's revenue was 4.10 billion yuan, up 19.54% year-on-year [38] - Taiji Group reported a net profit of 139 million yuan, a year-on-year decrease of 71.94% [39] - Taiji Group's revenue was 5.66 billion yuan, down 27.63% year-on-year [39] Group 15 - Suneng Co. reported a net profit of 93.19 million yuan, a year-on-year decrease of 90.13% [41] - Suneng Co.'s revenue was 5.57 billion yuan, down 17.15% year-on-year [41] - Three Gorges Water Conservancy reported a net profit of 47.93 million yuan, a year-on-year decrease of 79.07% [42] - Three Gorges Water Conservancy's revenue was 4.90 billion yuan, down 6.10% year-on-year [42] Group 16 - Furida reported a net profit of 108 million yuan, a year-on-year decrease of 15.16% [44] - Furida's revenue was 1.79 billion yuan, down 7.05% year-on-year [44] - Chenzhou Electric International achieved a net profit of 25.92 million yuan, a year-on-year increase of 29.55% [46] - Chenzhou Electric International's revenue was 1.96 billion yuan, up 1.26% year-on-year [46] Group 17 - Farlantek achieved a net profit of 122 million yuan, a year-on-year increase of 41.05% [47] - Farlantek's revenue was 1.18 billion yuan, up 46.63% year-on-year [47] - Huitai Medical reported a net profit of 425 million yuan, a year-on-year increase of 24.11% [48] - Huitai Medical's revenue was 1.21 billion yuan, up 21.26% year-on-year [48] Group 18 - Dameng Data's director is under investigation for suspected violations [49] - The company's daily operations remain normal [49] - Maiwei Co. reported a net profit of 394 million yuan, a year-on-year decrease of 14.59% [50] - Maiwei Co.'s revenue was 4.21 billion yuan, down 13.48% year-on-year [50] Group 19 - Waiservice Holdings achieved a net profit of 384 million yuan, a year-on-year increase of 5.51% [52] - Waiservice Holdings' revenue was 12.25 billion yuan, up 16.15% year-on-year [52] - Huakang Co. reported a net profit of 134 million yuan, a year-on-year decrease of 3.38% [53] - Huakang Co.'s revenue was 1.87 billion yuan, up 37.32% year-on-year [53] Group 20 - Bluelight Optical achieved a net profit of 103 million yuan, a year-on-year increase of 110.27% [54] - Bluelight Optical's revenue was 577 million yuan, up 52.54% year-on-year [54] - Shunwang Technology reported a net profit of 162 million yuan, a year-on-year increase of 69.22% [55] - Shunwang Technology's revenue was 1.01 billion yuan, up 25.09% year-on-year [55] Group 21 - Anbiping reported a net loss of 12.50 million yuan in the first half of 2025 [56] - Anbiping's revenue was 159 million yuan, down 30.11% year-on-year [56] - Jinhua Co. reported a net profit of 6.20 million yuan, a year-on-year decrease of 34.53% [57] - Jinhua Co.'s revenue was 241 million yuan, down 1.90% year-on-year [57] Group 22 - Xiehe Electronics achieved a net profit of 28.96 million yuan, a year-on-year decrease of 8.31% [59] - Xiehe Electronics' revenue was 451 million yuan, up 12.13% year-on-year [59] - Huguang Co. reported a net profit of 276 million yuan, a year-on-year increase of 8.40% [60] - Huguang Co.'s revenue was 3.63 billion yuan, up 6.20% year-on-year [60]

（记者 曾健辉） 每经头条（nbdtoutiao）——核心产品净值仅剩7毛钱，昔日"公募一哥"任泽松怎么了？牛市踏空真相曝 光 每经AI快讯，九强生物8月22日晚间发布公告称，北京九强生物技术股份有限公司于近日收到北京市药 品监督管理局颁发的《医疗器械注册证》。产品名称为"狼疮抗凝物检测试剂盒（凝固法）"。 ...